JAPAN BREAST CANCER RESEARCH GROUP
🇯🇵Japan
Clinical Trials
11
Active:0
Completed:5
Trial Phases
4 Phases
Phase 2:4
Phase 3:3
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Phase 2
4 (36.4%)Not Applicable
3 (27.3%)Phase 3
3 (27.3%)Phase 4
1 (9.1%)Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC
Phase 2
Recruiting
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: Induction therapy
- First Posted Date
- 2025-01-27
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 106
- Registration Number
- NCT06793553
- Locations
- 🇯🇵
Yukinori Ozaki, Koto-ku, 3-8-31, Tokyo, Japan
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Phase 3
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 480
- Registration Number
- NCT03264547
- Locations
- 🇯🇵
Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
🇯🇵National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
Phase 3
- Conditions
- HER2-positive Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 370
- Registration Number
- NCT02514681
- Locations
- 🇯🇵
Aichi Cancer Center, Chikusa-ku, Aichi, Japan
🇯🇵Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
Phase 2
Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
News
No news found